Chlorpheniramine spray label centers on short-term allergy relief in children and adults
Chlorpheniramine maleate now appears in a pediatric-branded aerosol spray label that frames the drug as an antihistamine for temporary relief of hay fever and other upper respiratory allergy symptoms. The listed uses are familiar to anyone who treats seasonal rhinitis: runny nose, itchy nose or throat, sneezing, and itchy, watery eyes. What changes here is the delivery format and the explicit age-based dosing guidance built into the label, with a peppermint-flavored oral spray designed for families navigating symptom control without moving immediately to prescription therapy.
The active ingredient is listed at 0.5% and the product is classified as a human OTC drug. In practical terms, the label positions the spray as a symptomatic treatment, not a disease-modifying intervention. Histamine blockade can blunt the nasal and ocular cascade triggered by allergen exposure, which is why first-generation antihistamines continue to hold a place in self-care despite newer options with less sedation.
Age cutoffs define the boundaries of safe home use
The dosing language is unusually specific. Adults and children 12 years and older are instructed to use four sprays per application every 4 to 6 hours, without exceeding six applications in 24 hours. Children 6 to under 12 years should be supervised and use two sprays every 4 to 6 hours, with a maximum of three applications in 24 hours. Children 4 to under 6 years should not use the product unless directed by a doctor, and children under 4 years should not use it at all.
Those age thresholds matter because first-generation antihistamines can be more sedating and less predictable in younger children. The label’s structure acknowledges that risk while still allowing use in older pediatric patients who can tolerate careful supervision. The spray format may also appeal to caregivers who are trying to manage bothersome symptoms quickly, but it does not remove the pharmacology that comes with chlorpheniramine exposure.
Dosing convenience does not cancel sedative burden.
Sedation, paradoxical excitability, and other warnings remain central
The warning section reads like a reminder that an apparently simple allergy product can still affect the central nervous system and airway physiology. Patients with glaucoma, breathing problems such as emphysema or chronic bronchitis, or trouble urinating due to an enlarged prostate gland are told to ask a doctor before use. Those taking sedatives or tranquilizers are also directed to seek pharmacist or physician guidance before use. The reason is straightforward: additive CNS depression can increase drowsiness and impair alertness, while anticholinergic effects can worsen urinary retention and complicate other chronic conditions.
The label explicitly says drowsiness may occur, alcohol should be avoided, and sedatives or tranquilizers can increase drowsiness. It also advises caution when driving or operating machinery. In children, excitability may occur instead of calm sedation, a classic first-generation antihistamine issue that can confuse caregivers who expect only sleepiness. The label further warns that the product should not be used to make a child sleepy, a line that reflects a long-standing safety concern around misuse of over-the-counter antihistamines in pediatric households.
A single antihistamine can push sedation in one direction and agitation in another.
Ingredient profile reflects a formulation built for tolerability and taste
Inactive ingredients include aloe vera, glycerin, grapefruit seed extract, hyaluronic acid, peppermint flavor, purified water, stevia, and xylitol. Those excipients suggest a formulation strategy aimed at mouthfeel, flavor masking, and mucosal comfort rather than systemic pharmacologic effect. For a pediatric product, taste and palatability are not cosmetic details; they affect whether a caregiver can administer the intended dose without resistance.
The product information lists the route of administration as oral, even though the dosage form is described as an aerosol spray. That combination indicates a sprayed oral delivery rather than a nasal antihistamine application. The distinction is clinically relevant because it affects onset expectations, patient counseling, and how families interpret the product’s role during an allergy flare.
Packaging, manufacturing, and OTC status frame the regulatory context
The label identifies package size as 15 mL in one bottle with applicator, packaged in a single carton, with an NDC code of 82643-011-15. Marketing began in April 2023 under OTC Monograph Drug category M012, and the label was updated on November 5, 2026. The packager and registrant are listed as FERRER MEDICAL INNOVATIONS LLC, and manufacturing is assigned to Xlear Inc.
A label can be clinically meaningful even when it is not tied to a new trial or a fresh efficacy claim. Here, the update reinforces approved over-the-counter use boundaries, pediatric supervision rules, and safety warnings that clinicians already emphasize in practice. Those details matter when families self-select allergy remedies from shelves or online listings, because a product marketed for children can still carry the standard limitations of first-generation antihistamines.
Breastfeeding, pregnancy, and overdose precautions remain explicit
The label advises pregnant or breastfeeding patients to ask a doctor before use. That guidance is broad, but it is appropriate for an OTC antihistamine with central effects and limited patient-specific context at the point of purchase. In the same cautionary spirit, the product is to be kept out of reach of children, and overdose should prompt immediate medical help or contact with a Poison Control Center.
For clinicians, the value of the label lies in how clearly it connects symptom relief with safety constraints. Parents may reach for a child-branded allergy spray because nasal symptoms are disruptive and easy to recognize. The label reminds them that symptomatic relief comes with age limits, supervision requirements, drowsiness risk, and interaction concerns that cannot be ignored simply because the product sits in an OTC aisle.
The formulation is designed for temporary relief, not routine casual use.
Inactivated NDC status adds a supply-chain footnote
The listing also notes that the SPL contains an inactivated NDC code, 82643-011-15. In regulatory terms, that means the code has been flagged in the FDA compliance context rather than serving as a live commercial identifier. For patients and clinicians, this is a reminder to check the current package labeling and product availability before assuming a specific stock-keeping identifier remains active.
The label does not introduce a new mechanism or a novel clinical claim. It does something more mundane and more useful: it spells out how a familiar antihistamine should be used, by whom, and under what cautions, with pediatric boundaries that are easy to overlook when allergy season drives self-treatment.